Research Conducted at Wake Forest University Has Updated Our Knowledge about Multiple Myeloma (Health-related Quality of Life In Transplant-eligible Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide,...).

A recent study conducted at Wake Forest University in Charlotte, North Carolina, has provided updated knowledge about multiple myeloma, a type of cancer. The study focused on the health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma who were treated with daratumumab, lenalidomide, bortezomib, and dexamethasone. Patient-reported outcomes were collected using various tools, and improvements in pain symptoms, global health status, fatigue symptoms, and physical functioning were observed with both treatment groups. These findings contribute to the evidence supporting the clinical benefits of this treatment approach. [Extracted from the article]